Slingshot members are tracking this event:
FDA Approves Abbott's Absorb Bioresorbable Stent, The Only Fully Disolving Heart Stent
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
In clinical studies conducted around the world, the Absorb bioresorbable stent demonstrated comparable short-term and mid-term outcomes to the leading metallic stent—Abbott's Xience drug eluting stent. At one year in a pre-specified group of approximately 2,000 U.S. patients in the pivotal ABSORB III randomized clinical trial, patients who received the dissolving Absorb stent experienced comparable rates of specific adverse events in the intended patient population (reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm)—including heart disease-related death, heart attacks attributed to the stented artery and repeat procedures at the treated lesion (collectively termed target lesion failure)—as compared to patients who received the metallic Xience stent.
Slingshot Insights Explained
Jul 05, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Metallic Xience Stent, Absorb Iii